TASC试验：镰状细胞病急性胸部综合征的治疗剂量与预防剂量抗凝对比

原文图文 · 图 32 张

REBEL Rundown

Key Points

The TASC trial is the first phase 3 RCT to demonstrate that a pharmacologic intervention can shorten the duration of acute chest syndrome (ACS) in sickle cell disease (SCD).

Therapeutic-dose tinzaparin reduced time to ACS resolution compared with prophylactic doses.

Opioid consumption was significantly lower in the therapeutic anticoagulation group.

No major or nonmajor bleeding occurred in either group, though the study excluded patients at higher bleeding risk (renal failure, extreme body weight, coagulopathy).

Results are promising but should be considered hypothesis-generating given the borderline significance.

Introduction

ACS is the most common cause of critical care admission and one of the leading causes of death in adults with sickle cell disease (SCD). Current management remains entirely supportive and includes hydration, analgesia, transfusion, antibiotics, and respiratory support with no pharmacologic therapy proven to shorten disease duration. Pathophysiologic evidence suggests that in situ pulmonary microthrombosis plays a central role in ACS. Despite this rationale, prior attempts to study anticoagulation in ACS have failed; the only previous trial enrolled just 7 patients over 4 years before terminating for futility. The authors of the TASC (multicenter, double-blind, randomized controlled trial) sought to determine whether therapeutic-dose anticoagulation with tinzaparin could shorten ACS duration compared with prophylactic doses in adult patients without macrovascular thrombosis. Tinzaparin is within the class of low lower molecular weight heparin (LMWH) however it has a higher molecular weight and greater anti-thrombin activity compared to others like enoxaparin. This contributes to its anti-inflammatory and anti-adhesive properties in addition to anticoagulation which is helpful specifically in SCD vaso-occlusive crises and its thromboinflammatory pathophysiology.

Paper

Mekontso Dessap A, et al. Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Double-Blind Controlled Randomized Clinical Trial. Am J Respir Crit Care Med. 2025. PMID: 40209087

PREVIOUSLY COVERED ON REBEL EM:

REBEL Core Cast 41.0 – Acute Chest Syndrome

Hematologic Emergencies in the Critical Care Setting Part 2

REBEL Core Cast 126.0 – Peds Hem Onc Emergencies

Rethinking Fluid Resuscitation in Vaso-Occlusive Crisis: Is Lactated Ringer’s the Superior Choice?

What They Did

CLINICAL QUESTION

In adults with sickle cell disease hospitalized for acute chest syndrome (ACS) without pulmonary artery macrothrombosis, does therapeutic-dose anticoagulation with tinzaparin shorten ACS duration compared with prophylactic-dose anticoagulation?

STUDY DESIGN

Type: Multicenter, double-blind, randomized controlled trial

Sites: 12 hospitals in France

Enrollment period: 2016-2021

Randomization: 1:1 to therapeutic vs prophylactic tinzaparin, stratified by hypoxemia (PaO₂/FiO₂ <300 mmHg)

POPULATION

Inclusion Criteria:

Age ≥18 years

SCD (Included the following genotypes: SS, SC, Sβ⁰, or Sβ⁺ thal)

Newly diagnosed ACSDefined as a new pulmonary infiltrate on chest X-ray or CT plus a respiratory symptom (chest pain, dyspnea, or cough) or abnormal pulmonary auscultation (crepitation, tubular breath sounds, or decreased vesicular breath sounds)

No pulmonary artery thrombosis on CTPA

Exclusion Criteria:

ACS diagnosis >48 hours prior

Body weight <40 kg or >100 kg

Creatinine clearance <60 mL/min

Clinical indication for therapeutic anticoagulation

Contraindications to therapeutic anticoagulation

High-risk for red blood cell transfusion complications

History of type II heparin-induced thrombocytopenia

Bleeding event or high risk for bleeding

Pregnant, breastfeeding, or postpartum

Under guardianship or curatorship

INTERVENTION & COMPARATOR

Intervention:

Therapeutic arm (n = 86): Tinzaparin 175 IU/kg/24h subcutaneously for 7 days or until hospital discharge

Comparator:

Prophylactic arm (n = 82): Tinzaparin 4,500 IU/24h subcutaneously for 7 days or until hospital discharge

Both groups received standard ACS management (hydration, pain control, antibiotics, transfusion per predefined criteria, oxygen/respiratory support)

OUTCOMES

Primary OutcomeSecondary Outcomes

Time to ACS resolution (defined by joint improvement of fever, chest pain, dyspnea, ± hypoxemia)

Hospital Discharge:

Cumulative dose of parenteral opioids (morphine equivalents)

Nonmajor bleeding

Need for and volume of transfusion/phlebotomy

Need for mechanical ventilation (noninvasive and invasive)

Catecholamine infusion

ICU admission and length of ICU stay

Length of hospital stay

All-cause death

At 6 months:

Hospital readmissions (all-cause and ACS-specific)

Thrombotic events (DVT, pulmonary artery thrombosis)

All-cause death

Results

Baseline Characteristics

Baseline Characteristics

Age, mean (SD), yr: 29.9 (8.7)

Sex, % female: 42% (84/198 enrolled)

SCD genotype: Majority SS

Critical Results

Primary safety (major bleeding): 0

Hospital deaths: 0

Invasive mechanical ventilation, n (%): 2 (2.4%), p > 0.99

Strengths

First trial to successfully evaluate drugs to shorten ACS duration.

Primary outcome was a patient oriented outcome.

Double-blind design with high compliance (~90–98%)

Exclusion of macrothrombosis identified on CTPA prior to randomization resulted in isolation of evaluating the effect of therapeutic anticoagulation on microthrombosis.

Internal consistency evident as there is concordant ACS duration reduction (HR 0.71) and lower opioid consumption (Δ −96 mg morphine equivalent).

No bleeding occurred, reassuring safety of treatment in this population.

Multicenter enrollment across 12 sites including overseas territories enhances generalizability.

Not only performed a 6-month follow up but looked at relevant outcomes at that point (ie hospital readmissions and all-cause death).

Limitations

Primary outcome being a composite outcome means that one big factor can weigh down all the others and ultimately skew the result.

Sample size is small (n = 168) underpowering secondary outcomes such as low rates of mechanical ventilation, ICU admission, and mortality.

Exclusion of comorbidities like extreme body weights, renal impairment, and high bleeding risk limits generalizability to sicker ACS population.

Other strict inclusion criteria like how ACS was defined and the lack of pulmonary artery thrombosis on CTA may limit enrollment and cause selection bias.

Borderline primary endpoint significance (P = 0.044): CI (0.99) of primary endpoint borderline nearly crosses 1.0. Additionally no multiplicity adjustment was applied across secondary endpoints.

Absence of placebo makes it difficult to determine if therapeutic anticoagulation is superior to no anticoagulation.

Results can only be applied to adults as ACS pathophysiology differs from the pediatric population (greater infectious etiology).

Patients were only from France which represents more homogenous patient population than a place like the United States.

Results may not generalize to other low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs) given tinzaparin’s unique pharmacologic profile.

Discussion

ACS is the leading cause of morbidity and mortality in SCD, with the pathogenesis being multifactorial including pneumonia, fat embolism, and pulmonary vascular occlusion from in situ thrombosis and sickling.3 11 Infectious etiologies are predominant. The National Acute Chest Syndrome Study Group identified an infectious agent in 54% of 671 ACS episodes, with atypical bacteria (Chlamydia pneumoniae and mycoplasma pneumoniae) and viruses (influenza and RSV) as the most common pathogens.3-6 Fat embolism from bone necrosis during severe vaso-occlusive crises can result in abrupt multiorgan failure, 100-fold increase in serum ferritin, and marked thrombocytopenia. 7-9 Pulmonary artery thrombosis has been identified in approximately 17% of adult ACS episodes on CT pulmonary angiography. These thromboses likely formed in situ rather than by embolism given absence of peripheral venous clots.10,11 The remaining cases are attributed to microvascular occlusion from direct sickling and clotting in the pulmonary vasculature, a mechanism that is not visible on standard imaging but is supported by autopsy data. 3, 10

The TASC trial sought to target in situ microthrombosis with therapeutic anticoagulation. The double-blind design of this study is a critical strength, especially since key outcomes (pain, dyspnea, opioid use) are subjective variables. Blinding of the patients, providers and assessors of outcomes drastically reduces the risk of performance and detection bias. Treatment compliance was high in both arms (~90-98%) resulting in strong internal validity of the intention-to-treat analysis.2

Systemically excluding pulmonary artery macrothrombosis by CTPA before randomization resulted in the trial specifically testing whether anticoagulation benefits ACS patients through microvascular mechanisms. This is important since patients with overt PE would have a clear indication for therapeutic anticoagulation.

However, no study is perfect and this one has several methodological concerns. The primary endpoint, that is, time to ACS resolution, is a composite requiring joint improvement of fever, chest pain, dyspnea, and hypoxemia. This endpoint was driven predominantly by faster resolution of pain and fever rather than improvement in oxygenation as only 38% of patients were hypoxemic.2 This composite has not been independently validated, and these subjective components, especially pain and dyspnea, may vary in assessment despite blinding. The borderline statistical significance (HR 0.71; 95% CI, 0.51–0.99; P = 0.044) is notable: the upper confidence interval bound barely excludes 1.0, and no adjustment for multiplicity was applied across the multiple secondary endpoints tested.

The concordance between the primary endpoint and the significant reduction in opioid consumption (Δ −96 mg morphine equivalent; P = 0.02) does provide reassuring internal consistency. However, the 1.3-day reduction in ACS duration did not translate into improvements in harder clinical outcomes such as hospital length of stay (median 7 vs. 6 days; P = 0.5), mechanical ventilation, ICU admission, or mortality.2 Despite this, the intervention was highly cost-effective given that a 7-day course of therapeutic LMWH cost is much cheaper than an average ACS hospitalization.

Another issue is the narrow eligibility criteria resulting in exclusion of patients with body weight <40 kg or >100 kg, creatinine clearance <60 ml/min, high bleeding risk, or need for urgent transfusion. As a result, a relatively lower-acuity population was selected. Only 37.5% of enrolled patients were hypoxemic at baseline.2 This raises an important question: were patients with severe ACS and significant pulmonary vascular compromise, who may have been most likely to benefit from therapeutic anticoagulation, underrepresented?

The absence of a placebo (no-anticoagulation arm) is another drawback. Since prophylactic anticoagulation is standard of care in France but not universally an adopted practice, the trial cannot determine whether therapeutic anticoagulation is superior to no anticoagulation.

Can we identify patients with ACS who don’t have PE on CTA but would benefit from anticoagulation? Although D-dimer is a biomarker that can be helpful in general practice to identify PE, its utility in SCD is limited due to baseline hypercoagulable state. 97% of patients with vaso-occlusive crisis and 85% with other SCD complications were found to have elevated levels compared to 10% of asymptomatic patients.12 In ACS specifically, D-dimer elevation was seen in 95% of cases reflecting lack of utility for diagnosing in situ thrombosis. 11,12

Another limitation of the study is that tinazaparin, the primary anticoagulant evaluated in this study, is not available in the United States. Tinzaparin was voluntarily withdrawn from the US market by its manufacturer primarily because it could not compete with enoxaparin’s dominant market, broader FDA indications, and FDA boxed warning regarding increased mortality risk in elderly patients and those with renal insufficiency. Comparisons of tinzaparin with enoxaparin for secondary VTE prevention suggest equivalence,13 and tinazaparin appears comparable to unfractionated heparin.14 Although head-to-head comparison in acute coronary syndromes showed enoxaparin is superior15, there are no studies comparing these agents in the treatment of acute thrombotic disorders. Therefore, TASC results may not be directly transferable to enoxaparin. Additionally, tinazaparin has a unique pharmacalogic profile as it has a lower anti-Xa/anti-IIa ratio providing more balanced thrombin inhibition and tissue factor pathway modulation.2 This may contribute to the observed benefits beyond pure anticoagulation.

Author's Conclusion

“In adult patients with ACS, a therapeutic anticoagulation shortened ACS duration and reduced opioid consumption compared with prophylactic doses, without increasing bleeding risk.”

Our Conclusion

This trial provides the first convincing evidence that a pharmacologic intervention can shorten ACS duration in SCD, likely by targeting in situ microthrombosis resulting in faster resolution and reduced opioid use. Overall clinical impact on health systems unclear given study did not demonstrate shorter hospital stays, reduced need for ventilatory support, or lower mortality. Given small trial and a p value of 0.044 in primary outcome, future studies applied to broader populations including no-anticoagulation arm, sicker patients, and pediatric populations need to be done.

Clinical Bottom Line

The TASC trial is the first RCT to demonstrate that any drug, in this case therapeutic-dose LMWH, can shorten ACS duration in SCD (1.3 days) and half opioid use with zero bleeding events. For adult SCD patients with ACS and no contraindication, therapeutic anticoagulation should be strongly considered even when CTA excludes PE.

Guest Authors

Heba Zakaria, MD

PGY-2 Emergency Medicine Resident

Northwestern University, Chicago, IL

David Zull, MD

Professor of Emergency Medicine

Northwestern University, Chicago, IL

Showing Slide 1 of 2

References

Mekontso Dessap A, et al.

Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease: The TASC Double-Blind Controlled Randomized Clinical Trial. Am J Respir Crit Care Med. 2025

PMID: 40209087

Vichinsky EP, et al.

Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000

PMID: 10861320

Neumayr L, et al.

Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics. 2003

PMID: 12837872

Miller ST, et al.

Role of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr. 1991

PMID: 1898750

Assad Z, et al.

Unique Changes in the Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Unravel the Role of Respiratory Pathogens: A Time Series Analysis. Chest. 2024

PMID: 37544426

Salam, A, et al.

Clinical, laboratory, radiological features, and outcome of acute fat embolism syndrome in sickle cell disease. Sci Rep. Published Jul 2025

PMID: 40721454

Tsitsikas DA, et al.

Fat Embolism Syndrome in Sickle Cell Disease. J Clin Med. Published Nov 2020

PMID: 33171683

Bosch A, et al.

Identifying and Treating Severe Bone Marrow Necrosis and Fat Embolism Syndrome in Pediatric Patients With Sickle Cell Disease: A Case Report. J Pediatr Hematol Oncol. 2022

PMID: 35082243

Dessap, A. M., et al.

Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011

PMID: 21836136

Miller AC, & Gladwin MT.

Pulmonary Complications of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine (2012)

PMID: 22447965

Devine DV, et al.

Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood. 1986.

PMID: 3719103

Trujillo‐ Santos J, et al.

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Research and Practice in Thrombosis and Haemostasis, Jun 2022

PMID: 35664535

Hoy SM, et al.

Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. Exp Hematol Oncol. Aug 2013

PMID: 2056883

Wong GC, et al.

Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003

PMID: 20568836

Post Peer Reviewed By: Mark Ramzy, DO (X/IG: @MRamzyDO), and Anand Swaminathan, MD (X/IG: @EMSwami)

Your Deep-Dive Starts Here

Rethinking Fluid Resuscitation in Vaso-Occlusive Crisis: Is Lactated Ringer’s the Superior Choice?

Background: Sickle cell disease (SCD) affects an estimated 300,000 infants born worldwide each ...

Hematology and Oncology

Read More

REBEL Core Cast 126.0 – Peds Hem Onc Emergencies

Take Home Points Early administration of antibiotics (within 60 min) in patients with ...

Hematology and Oncology

Read More

Hematologic Emergencies in the Critical Care Setting Part 2

Background: Hematologic emergencies in the critical care setting are rare but deadly complications ...

Hematology and Oncology

Read More

Hematologic Emergencies in the Critical Care Setting Part 1

Background: Hematologic emergencies in the critical care setting are rare but deadly complications ...

Hematology and Oncology

Read More

REBEL Core Cast 41.0 – Acute Chest Syndrome

Take Home Points 100k people in US have sickle cell, the majority will ...

Cardiovascular

Read More

Showing Slide 1 of 5: Rethinking Fluid Resuscitation in Vaso-Occlusive Crisis: Is Lactated Ringer’s the Superior Choice?

The post The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome appeared first on REBEL EM - Emergency Medicine Blog.